Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
66 results about "Aβ oligomers" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This stimulates the host immune system to recognize and attack Aβ, or provide antibodies that either prevent plaque deposition or enhance clearance of plaques or Aβ oligomers. Oligomerization is a chemical process that converts individual molecules into a chain consisting of a finite number of molecules.
Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof
ActiveUS20100028357A1Harmful side-effectsSuppresses senile plaque amyloid formationNervous disorderImmunoglobulins against animals/humansDiseaseOligomer
The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:NAT CENT FOR GERIATRICS & GERONTOLOGY +1
Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
InactiveUS20060240486A1Rapid improvement in cognitionImprove bindingCompound screeningApoptosis detectionAβ oligomersAmyloid
In various aspects, the present invention provides methods and kits for predicting the therapeutic efficacy of an immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder by comparing the amount of Aβ monomer in an Aβ preparation which binds to the immunological reagent to an amount of one or more Aβ oligomers in the Aβ preparation which bind to the immunological reagent to determine a relative bound amount, and predicting the efficacy of the immunological reagent, identifying an immunological reagent having therapeutic efficacy, or both, for the treatment of an amyloidogenic disorder based at least on the relative bound amount.
Owner:JANSSEN ALZHEIMER IMMUNOTHERAPY +1
Antibody Specific Binding to A-Beta Oligomer and the Use
InactiveUS20100291071A1Harmful side-effectsSuppresses senile plaque amyloid formationNervous disorderImmunoglobulins against animals/humansDiseaseOligomer
The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA +1
Antibodies That Specifically Bind to A Beta Oligomers and Use Thereof
The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA
Antibody Specific Binding to A Beta Oligomer and the Use
InactiveUS20100260783A1Harmful side-effectsSuppresses senile plaque amyloid formationNervous disorderHybrid immunoglobulinsDiseaseOligomer
The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA +1
Nucleic acid aptamer electrochemical sensor based on metal organic framework materials as signal probes
ActiveCN108169303AEasy to passSimplify detection stepsMaterial electrochemical variablesAptamerAβ oligomers
The invention relates to a nucleic acid aptamer electrochemical sensor based on metal organic framework materials (MOFs) as signal probes. The senor is used for detection of beta-amyloid (A beta) oligomers and belongs to the technical field of functional nanocomposite materials and biosensor detection. AuNFs-modified glassy carbon electrodes immobilize a first layer of aptamers, the A beta oligomer is further identified and through combination with second layer aptamer-modified gold nanoparticle-loaded Cu-MOFs (AuNPs / Cu-MOFs), the sandwich electrochemical sensor for detection of the A beta oligomer is formed. AuNPs / Cu-MOFs as a redox medium can directly detect a Cu<2+> signal and electrochemically active molecule labeling is avoided so that the detection processes are greatly simplified and the sensitivity of detection is improved.
Owner:SHANGQIU NORMAL UNIVERSITY
Composition and Method for a Producing Stable Amyloid Beta Oligomers of High Molecular Weight
InactiveUS20100240868A1Enhance oligomer stabilityStable preparationDepsipeptidesPeptide preparation methodsHigh concentrationAntigen
The invention relates to a method for the preparation of a stable, soluble amyloid beta (Aβ) oligomer and composition thereof for use as an antigen for the generation of antibodies for the treatment of Alzheimer's disease and other conditions related to abnormal amyloid beta aggregation. The method which uses a pH in excess of 7.0 and high concentrations of Aβ, optionally includes the use of divalent anions or a helix-inducing solvent to form the oligomers. The stable, soluble Aβ oligomers produced by the method herein have a particle size of 10 to 100 nm in diameter, when measured by a dynamic light scattering technique, and a molecular weight of 100 to 500 kDa.
Owner:MERCK SHARP & DOHME CORP
Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease
InactiveUS20130156705A1Aid in diagnosisUltrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsAβ oligomersCholesterol
Bivalent multifunctional Aβ oligomerization inhibitors (BMAOIs) that target multiple risk factors involved in Alzheimer's disease are provided. The BMAOIs are useful for the treatment and / or prevention of Alzheimer's disease, as well as for diagnostic imaging of Aβ plaques in brain tissue. The BMAOIs comprise i) an Aβ oligomer (ApO)-inhibitor moiety which may have antioxidant activity (e.g. curcumin, curcumin derivatives, curcumin hybrids, resveratrol, etc.); ii) a cell membrane / lipid raft (CM / LR) anchoring moiety (e.g. cholesterol, cholesterylamine, a steroid, etc.); and iii) a spacer or linker moiety that stably links i)
![Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease](https://images-eureka.patsnap.com/patent_img/b6f1ef30-db99-464a-af14-3e6a245382f3/US20130156705A1-20130620-D00001.png "Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease")
![Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease](https://images-eureka.patsnap.com/patent_img/b6f1ef30-db99-464a-af14-3e6a245382f3/US20130156705A1-20130620-D00002.png "Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease")
![Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease](https://images-eureka.patsnap.com/patent_img/b6f1ef30-db99-464a-af14-3e6a245382f3/US20130156705A1-20130620-D00003.png "Bivalent multifunctional ligands targeting a[beta] oligomers as treatment for alzheimer's disease")
Owner:VIRGINIA COMMONWEALTH UNIV
Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof
InactiveUS20110097319A1Suppress Aβ amyloid fibril formationAvoid developmentNervous disorderImmunoglobulins against animals/humansDiseaseOligomer
The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA +1
Anti-Alzheimer disease monoclonal antibody and application thereof
ActiveCN101531717AHigh titer of immune serumGood immune effectNervous disorderImmunoglobulins against animals/humansOligomerAβ oligomers
The invention provides an anti-Alzheimer disease monoclonal antibody which can specifically identify and combine Abeta oligomers and can be used in the preparation of diagnostic reagents and treatment drugs for Alzheimer disease.
Owner:BEIJING JIAOTONG UNIV
Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
InactiveUS20130052670A1Reliable detectionImmunoglobulins against animals/humansDisease diagnosisTarget engagementOligomer
The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and / or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and / or target engagement.
Owner:MERCK & CO INC
Application of Alpha-mangostin in preparing medicines for treating Alzheimer's disease
The invention discloses novel medical application of Alpha-mangostin, i.e. application of Alpha-mangostin in preparing medicines for treating Alzheimer's disease. Under a brand-new working concentration, the Alpha-mangostin shows the characteristic of restricting A Beta accumulation and deposition, simultaneously has a neuroprotection role, can effectively resist a neurotoxin role caused by A Beta oligomer, strengthen the normal physiological function of neuron cells of mammals and maintain the normal cell form of the neuron cells of the mammals, realizes the intervention to the pathological course of the Alzheimer's disease and the improvement to the pathological symptoms and provides a new path for treatment of the Alzheimer's disease.
Owner:BOMAI
Design of a peptide probe for rapid and specific detection of amyloid aggregation
InactiveUS20120009685A1Reduce decreasePromote aggregationPeptidesBiological testingSpecific detectionAβ oligomers
A peptide probe that generates fluorescence signals rapidly upon recognition of various Aβ aggregates without significant perturbation of samples. The present peptide probes display an increase in fluorescence signals upon coincubation with Aβ oligomers, but neither monomeric / dimeric species nor fibrils. The detection can occur within an hour or two without any additional sample preparation and incubation steps.
Owner:POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY
Antibodies that specifically bind to A beta oligomers and use thereof
ActiveCN102574915AEstablish early diagnostic markersHybrid immunoglobulinsNervous disorderAβ oligomersMonoclonal antibody
The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA
Monoclonal antibodies targeting amyloid beta oligomers
ActiveUS20130295095A1Lower Level RequirementsHigh oligomerizationAnimal cellsNervous disorderEpitopeAβ oligomers
The invention relates to binding molecules capable of specifically recognizing soluble oligomers of N-terminal truncated Aβ starting with pyroglutamate (AβρE), pharmaceutical compositions comprising same, and their respective therapeutic uses. Particularly, the invention relates to an antibody molecule capable of specifically recognizing Aβ oligomers, wherein said antibody binds and / or detects an epitope as bound and / or detected by antibody PG3-38 9D5H6 as deposited under DSM AC-C3056. Further, the invention provides a method of inhibiting the formation or the seeding effect of said AβρE oligomers, and a method for identifying agents useful in the treatment and / or prevention of an amyloid-related disorder as well as methods of diagnosing a subject suspected of suffering from a disease associated with amyloidogenesis and / or amyloid plaque formation and to methods of monitoring the efficacy of a treatment of a disease associated with amyloidogenesis and / or amyloid-plaque formation characterized by the presence of Aβ oligomers in a subject.
Owner:SYNAPTIC SYST GESELLSCHAFT FUR NEUROBIOLOGISCHE FORSCHUNG ENTWICKLUNG & PROD MBH +1
Antibodies That Specifically Bind to ABeta Oligomers and Uses Thereof
ActiveUS20120141477A1Suppress Aβ amyloid fibril formationAvoid developmentNervous disorderImmunoglobulins against animals/humansAβ oligomersMonoclonal antibody
The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA +1
Anti-Aβ oligomer humanized antibody
ActiveUS8303954B2Nervous disorderAntibody mimetics/scaffoldsTherapeutic antibodyAntiendomysial antibodies
Owner:KYOWA HAKKO KIRIN CO LTD
Compositions and methods for treating a -modulated disease or disorder or improving cognition in a subject
ActiveUS20140371233A1Improving and preventing of and cognitionImproving and preventing further loss of and cognitionOrganic active ingredientsOrganic chemistryAβ oligomersCognition
The present invention provides compositions and methods for treating and preventing an Aβ-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits Aβ oligomer induced signaling and reduces or halts the progression of Alzheimer's Disease.
Owner:YALE UNIV
Antibodies, Kit and Method for Detecting Amyloid Beta Oligomers
ActiveUS20130130288A1High affinityImmunoglobulins against animals/humansDisease diagnosisAβ oligomersHer Disease
This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and / or to stratify AD patients according to the severity of their disease.
Owner:MERCK SHARP & DOHME LLC +1
Anti-abeta oligomer humanized antibody
ActiveUS20120009180A1Nervous disorderAntibody mimetics/scaffoldsAntiendomysial antibodiesAβ oligomers
An anti-cognitive dysfunction agent comprising a humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers and a fragment thereof as an active ingredient, and an therapeutic antibody which can be treat Alzheimer's disease by specifically binding amyloid β protein oligomer (Aβ oligomer) which is considered to be a cause of Alzheimer's disease are required. The present invention can provide an anti-Aβ oligomer humanized antibody and a method for treating Alzheimer's disease using the humanized antibody. An agent for treating Alzheimer's disease; an agent for suppressing formation of neuritic plaque; an inhibitor of formation of Aβ amyloid fiber; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the humanized antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the humanized antibody.
Owner:KYOWA HAKKO KIRIN CO LTD
Monoclonal antibodies targeting amyloid beta oligomers
ActiveUS8795664B2Lower Level RequirementsHigh oligomerizationAnimal cellsNervous disorderEpitopeAβ oligomers
Owner:SYNAPTIC SYST GESELLSCHAFT FUR NEUROBIOLOGISCHE FORSCHUNG ENTWICKLUNG & PROD MBH +1
Anti-Aβ oligomer humanized antibody
Owner:KYOWA HAKKO KIRIN CO LTD
Agents for treating alzheimer's disease
InactiveUS20130143822A1Improve bindingUndesirable immune response to the secretion section can be prevented or suppressedNervous disorderSugar derivativesAβ oligomersAlzheimer's disease
Agents for treating Alzheimer's disease comprising a peptide according to sequence no. 1 which binds to Aβ oligomers and thus results in the healing or alleviation of Alzheimer's disease. In further embodiments peptides are provided which contain a sequence no. 1, but have preceding sequence sections which allow the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided.
Owner:FORSCHUNGSZENTRUM JULICH GMBH
Preparation process for A beta oligomer antibody
ActiveCN106519029AIncrease flow rateSuitable for industrial productionImmunoglobulins against animals/humansPeptide preparation methodsVirus inactivationOligomer
The invention discloses a preparation process for an A beta oligomer antibody. The preparation process comprises the following steps that the conductivity, the pH and the protein concentration of an upper chromatographic column front sample are adjusted; affinity gel chromatography is conducted; eluent from an affinity chromatographic column is filtered, ultra-filtered and prepared; and virus inactivation and sterilized sub-packaging are conducted. According to the preparation process for the A beta oligomer antibody, one-step affinity chromatography is adopted, the purification multiple is 85-100 times, and the A beta oligomer antibody obtained through purification is high in concentration and clear in targeting performance and has wide clinical application prospects.
Owner:SHANDONG TAIBANG BIOLOGICAL PROD CO LTD +1
Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
InactiveUS20150064734A1Useful in treatmentMicrobiological testing/measurementDrug screeningDiseaseAβ oligomers
The present invention provides a method for screening a therapeutic and / or prophylactic agent for Alzheimer's disease using at least one index selected from the group consisting of the levels of Aβ oligomers, BiP, cleaved caspase 4, PRDX4 and ROS in nerve cells or the like whose differentiation has been induced from iPS cells derived from somatic cells of a patient with Alzheimer's disease.
Owner:KYOTO UNIV
Stabilized amyloid-beta oligomers and uses thereof
ActiveUS20130274437A1Peptide/protein ingredientsPeptide preparation methodsAβ oligomersAmyloid beta oligomer
The present invention pertains to stabilized Aβ oligomer compositions. Methods for generating stabilized Aβ oligomer compounds are also provided herein. Additionally, screening assays employing the Aβ oligomer compounds and methods for generating therapeutics with the Aβ oligomers are also provided. In a particular embodiment, the Aβ oligomer described herein is comprised of Aβ42 peptide.
Owner:PRESYMPTO INC
Antibodies that specifically bind to A beta oligomers and use thereof
The present inventors successfully produced monoclonal antibodies that are specific to only soluble A beta oligomers, but do not recognize soluble A beta monomers, which are physiological molecules. It was demonstrated that the anti-bodies are useful as diagnostic / therapeutic monoclonal antibodies for Alzheimer's disease.
Owner:IMMUNAS PHARMA
Polypeptide and gene vaccine used for treating alzheimer disease
InactiveCN103450347APrevent oligomerizationBlock hydrophobic interactionsNervous disorderGenetic material ingredientsAntigenAβ oligomers
The invention discloses a polypeptide used for treating alzheimer disease (AD). The amino acid sequence of the polypeptide is Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala. The polypeptide is smart in concept, an Abeta1-42 carboxyl terminal polypeptide Abeta31-42 is taken as an antigen, Th1 immune cell mediated self immunity inflammatory reactions, induced by Abeta16-30, are avoided, an organism can also be effectively induced to produce an antibody for identifying an Abeta1-42 carboxyl terminal, Abeta oligomerization is prevented, neurovirulence of an Abeta oligomer is effectively inhibited, and the aim of treating AD is achieved.
Owner:SICHUAN BAILI PHARM CO LTD
Method for detecting and accelerating beta-amyloid protein aggregation by means of lanthanide fluorescence complex
ActiveCN105973856AEasy to detectEasy diagnosisPreparing sample for investigationFluorescence/phosphorescenceFiberAβ oligomers
The invention discloses a method for detecting and accelerating beta-amyloid protein aggregation by means of a lanthanide fluorescence complex, and belongs to the technical field of medicines. According to the method, the lanthanide fluorescence complex is used for detecting A-beta aggregate, an imidazo[1,2,a]pyridine derivative serves as an antenna group to be coupled with a europium (III)-DTPA luminescence center to prepare a fluorescence complex Eu-L, the antenna group can be selectively combined with A-beta hydrophobic region amino acid residues with the beta-folding conformation, photoinduced electron transfer of amino acid hinders energy transfer from the antenna group to europium (III), Eu-L fluorescence is reduced, and the A-beta aggregate is detected by means of fluorescence changes. According to the method, the lanthanide fluorescence complex is further used for accelerating A-beta aggregation, on the basis of high affinity of the antenna ligand and the A-beta aggregate, the Eu-L can accelerate conversion of A-beta oligomers into corpus fibrosum, the A-beta aggregation process is simultaneously monitored by means of autofluorescence, and a good application prospect in the aspect of AD diagnosis and treatment is achieved.
Owner:NANJING UNIV OF TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com